

ADVANCED COURSE PROGRAMME

Clinical Questions in Advanced Bladder and Renal Cell Carcinoma

**ESMO VIRTUAL
ADVANCED COURSE**

**ONLINE
20-21 JUNE 2022**

Chairs:

Ravindran Kanesvaran, Singapore
Anja Lorch, Switzerland

ESMO VIRTUAL ADVANCED COURSE PROGRAMME CLINICAL QUESTIONS IN ADVANCED BLADDER AND RENAL CELL CARCINOMA

20-21 June 2022

CO-CHAIRS: Anja Lorch, Switzerland
Ravindran Kanesvaran, Singapore

SPEAKERS: Laurence Albiges, France
Richard Cathomas, Switzerland
Darren M. C. Poon, Hong Kong
Thomas B. Powles, United Kingdom
Manuela Schmidinger, Austria
Puay Hoon Tan, Singapore

LEARNING OBJECTIVES

- To understand essentials in the assessment and the value of multidisciplinary management of advanced bladder and renal cell carcinoma (RCC)
- To learn about state-of-the-art advances in treatment of advanced bladder and renal cell carcinoma
- To learn the principles of management of advanced bladder and renal cell carcinoma through direct exposure to real clinical scenarios

ACCREDITATION

The programme of this virtual event has been accredited with **6 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano, Switzerland
Email: courses@esmo.org
www.esmo.org



All timings are to be considered GMT+8 (Singapore Local Time)

Monday, 20 June 2022

15:00-15:05 **Welcome and course overview**

5' Anja Lorch, CH
Ravindran Kanesvaran, SG

15:05-15:45 **Session 1**
State-of-the-art in Urothelial Cancer (UC) and Renal Cell Carcinoma (RCC) pathology and molecular pathology
(Chair/Moderator: Ravindran Kanesvaran, SG)

15' Update in pathology and molecular pathology: RCC
Puay Hoon Tan, SG

15' Update in pathology and molecular pathology: UC
Puay Hoon Tan, SG

10' Discussion
Faculty

15:45-15:55 ***Virtual Break***

15:55-16:50 **Session 2**
Management of mUC
(Chair/Moderator: Anja Lorch, CH)

15' Updates on 1st line management of mUC
Richard Cathomas, CH

15' 2nd Line and Beyond: The art and science of sequencing treatments in mUC
Thomas B. Powles, UK

15' Adverse Effect (AE) management: New drugs, New AEs
Darren M. C. Poon, HK

10' Discussion
Faculty

16:50-18:00	Session 3 Management of mRCC (Chair/Moderator: Ravindran Kanesvaran, SG)
15'	Updates on 1 st line management of mRCC Anja Lorch, CH
15'	2 nd Line and Beyond: The art and science of sequencing treatments in mRCC Laurence Albiges, FR
15'	Updates on management of non-clear cell mRCC Manuela Schmidinger, AT
15'	AE management in mRCC Ravindran Kanesvaran, SG
10'	Discussion Faculty

Tuesday, 21 June 2022

15:00-15:40	Session 4 New treatments on the horizon (Chair/Moderator: Ravindran Kanesvaran, SG)
15'	mUC: What's on the horizon – new treatments Thomas B. Powles, UK
15'	mRCC: What's on the horizon – new treatments Laurence Albiges, FR
10'	Discussion Faculty
15:40-18:05	Workshops sessions Three workshops sessions 15' Introduction based on clinical cases presented by speakers 30' Discussion
Workshop 1	Clinical cases in mUC Anja Lorch, CH Darren M. C. Poon, HK
45'	
16:25-16:35	Virtual Break

Workshop 2 45'	Clinical cases in mRCC (clear cell) Laurence Albiges, FR Ravindran Kanesvaran, SG
Workshop 3 45'	Clinical cases in mRCC (non-clear cell) and rare bladder cancers (e.g. adenocarcinoma) Thomas B. Powles, UK Manuela Schmidinger, AT
18:05-18:10 5'	Synthesis and wrap-up Anja Lorch, CH Ravindran Kanesvaran, SG